These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33470890)

  • 1. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
    Hirabayashi Y; Maki K; Kinoshita K; Nakazawa T; Obika S; Naota M; Watanabe K; Suzuki M; Arato T; Fujisaka A; Fueki O; Ito K; Onodera H
    Nucleic Acid Ther; 2021 Apr; 31(2):114-125. PubMed ID: 33470890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
    Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
    J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
    Qu Y; Henderson KA; Harper TA; Vargas HM
    Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
    Goyenvalle A; Jimenez-Mallebrera C; van Roon W; Sewing S; Krieg AM; Arechavala-Gomeza V; Andersson P
    Nucleic Acid Ther; 2023 Jan; 33(1):1-16. PubMed ID: 36579950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics.
    Ramsden D; Belair DG; Agarwal S; Andersson P; Humphreys S; Dalmas DA; Stahl SH; Maclauchlin C; Cichocki JA
    ALTEX; 2022; 39(2):273–296. PubMed ID: 34766620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases.
    Paul D; Miller MH; Born J; Samaddar S; Ni H; Avila H; Krishnamurthy VR; Thirunavukkarasu K
    Expert Opin Drug Discov; 2023 Feb; 18(2):193-206. PubMed ID: 36562410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.
    Moffit JS; Blanset DL; Lynch JL; MacLachlan TK; Meyer KE; Ponce R; Whiteley LO
    Hum Gene Ther; 2022 Nov; 33(21-22):1126-1141. PubMed ID: 35994386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
    Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
    Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
    Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
    Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.